Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ system
暂无分享,去创建一个
Hiroyuki Shimada | Peter Pytel | M John Hicks | Armita Bahrami | T. Stricker | H. Shimada | A. Bahrami | W. London | P. Zage | S. Cohn | E. Perlman | W. Furman | M. Hicks | P. Pytel | Wendy B London | Susan L Cohn | Julie R. Park | Julie R Park | Y. Gosiengfiao | Elizabeth J Perlman | J. Shohet | A. Chlenski | H. Salwen | K. Maclean | Jason M Shohet | Kirsteen H Maclean | Alexandre Chlenski | Helen R Salwen | Wayne Furman | Thomas P Stricker | Andres Morales La Madrid | Lisa Guerrero | Yasmin Gosiengfiao | Peter E Zage | Rie Suganuma | Sara So | A. Morales La Madrid | L. Guerrero | R. Suganuma | Sara So
[1] Antonio Ortega,et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. , 2006, Journal of the National Cancer Institute.
[2] R. Stallings,et al. A 6-gene signature identifies four molecular subgroups of neuroblastoma , 2011, Cancer Cell International.
[3] Qing-Rong Chen,et al. Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma , 2004, Cancer Research.
[4] R. Arceci. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report , 2009 .
[5] K K Matthay,et al. The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.
[6] Scott L. Pomeroy,et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples , 2011, Acta Neuropathologica.
[7] Rakesh Nagarajan,et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. , 2009, The Journal of clinical investigation.
[8] J. Mora,et al. A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma , 2012, Clinical Cancer Research.
[9] A. Montag,et al. Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation , 2013, Modern Pathology.
[10] W. Furman,et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Meghana Kulkarni. Digital multiplexed gene expression analysis using the NanoString nCounter system. , 2011, Current protocols in molecular biology.
[12] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[13] John M Maris,et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[14] Gudrun Schleiermacher,et al. Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature , 2010, Clinical Cancer Research.
[15] W. Gerald,et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. , 2006, Cancer research.
[16] Afshin Mashadi-Hossein,et al. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System , 2009, BMC Research Notes.
[17] J. Maris. Recent advances in neuroblastoma. , 2010, The New England journal of medicine.
[18] P. Houghton,et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Fernandez,et al. Using Digital RNA Counting and Flow Cytometry to Compare mRNA with Protein Expression in Acute Leukemias , 2012, PloS one.
[20] A. Rademaker,et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Roland Eils,et al. Prognostic impact of gene expression-based classification for neuroblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Houghton,et al. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma , 2012, Investigational New Drugs.
[23] Jennifer L. Osborn,et al. Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.
[24] K. Matthay,et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] O. Yanuka,et al. Involvement of Myc targets in c-myc and N-myc induced human tumors , 1998, Oncogene.
[26] Roland Eils,et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling , 2004 .
[27] J Pritchard,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] K. Morik,et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles , 2010, International journal of cancer.
[29] John D. Storey. A direct approach to false discovery rates , 2002 .
[30] Ruth Ladenstein,et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. , 2009, The Lancet. Oncology.